NEW YORK – Agilent Technologies and Danish digital pathology software firm Visiopharm said on Monday they will comarket Visiopharm's portfolio of AI-driven pathology solutions.
The deal addresses the unmet needs of pathology labs, the partners said, adding the goal is to provide technologies, products, and services that will improve the standardization of pathology labs and accelerate accurate diagnoses.
Financial and other terms of the agreement were not disclosed.
"Agilent's market-leading portfolio of pathology staining management solutions combined with Visiopharm's digital interpretation solutions will help facilitate improved patient care and diagnostic accuracy," Agilent Vice President and General Manager of the pathology group Simon Østergaard said in a statement.